Thanks @stockrock , you at least received a response by making a...

Thanks @stockrock , you at least received a response by making a call, fantastic effort, I sent an email earlier in the week with slightly different questions but the same intent but have not received a response as yet. I will certainly post if I get a response.
So what I take away from this is that unless the premilinary primary endpoint failed badly the DMC could suggest they can continue the trial if they wish. MSB could then decide now that they have $40M to continue with the trail and we will need to wait to determine if a marketing/distribution partner is interested once the trial provide some hard efficacy data. Is that a fair conclusion?
I have no concept of how much info the DMC will give out in relation to the interim Futlity Test or how it could be used in discussions with the FDA re adjustment that could be made to the P3 trial do you? I never expected patient level data to be released at the interim analysis readout but did expect it would provide clear Infomation to MSB so that "subsequent strategic decisions around the program will be made" SI words back in July last year.